<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>OBJECTIVE: In order to investigate the potential role of <z:e sem="disease" ids="C0598608" disease_type="Disease or Syndrome" abbrv="">hyperhomocysteinemia</z:e> as an additional risk factor for thrombotic events, we studied its prevalence in patients with <z:e sem="disease" ids="C0409980" disease_type="Disease or Syndrome" abbrv="">primary antiphospholipid syndrome</z:e> (APS) and evaluated its association with different clinical features </plain></SENT>
<SENT sid="1" pm="."><plain>METHODS: We enrolled 29 patients without any current evidence of underlying <z:e sem="disease" ids="C0009782" disease_type="Disease or Syndrome" abbrv="">connective tissue disorder</z:e> and fulfilling the Sapporo preliminary classification criteria for APS </plain></SENT>
<SENT sid="2" pm="."><plain>RESULTS: Ten (34,4%) patients showed mild <z:e sem="disease" ids="C0598608" disease_type="Disease or Syndrome" abbrv="">hyperhomocysteinemia</z:e> (18,34 micromol/L +/- 2,04 DS) </plain></SENT>
<SENT sid="3" pm="."><plain>Nine had history of cerebrovascular disease, isolated (3 cases) or more often (6 cases) in association with other APS features </plain></SENT>
<SENT sid="4" pm="."><plain><z:hpo ids='HP_0000001'>All</z:hpo> patients, but one, showed multiple ischemic <z:e sem="disease" ids="C0221505" disease_type="Disease or Syndrome" abbrv="">cerebral lesions</z:e> </plain></SENT>
<SENT sid="5" pm="."><plain>Seven of the 10 patients with <z:e sem="disease" ids="C0598608" disease_type="Disease or Syndrome" abbrv="">hyperhomocysteinemia</z:e> had multiple <z:hpo ids='HP_0003613'>antiphospholipid antibody positivity</z:hpo> and presented more frequently (6 cases) multi-site vascular involvement </plain></SENT>
<SENT sid="6" pm="."><plain>CONCLUSIONS: The frequency of <z:e sem="disease" ids="C0598608" disease_type="Disease or Syndrome" abbrv="">hyperhomocysteinemia</z:e> in patients with primary APS is not negligible and appears to be associated with cerebral microangiopathic disease, multiple <z:hpo ids='HP_0003613'>antiphospholipid antibody positivity</z:hpo> and the simultaneous involvement of different vascular districts </plain></SENT>
<SENT sid="7" pm="."><plain>For this reason and because <z:e sem="disease" ids="C0598608" disease_type="Disease or Syndrome" abbrv="">hyperhomocysteinemia</z:e> can be easily corrected with safe and relatively inexpensive therapeutic interventions, we advocate the measurement of homocysteinemia in every patient affected by APS and possibly in subjects with positive <z:hpo ids='HP_0003613'>antiphospholipid antibody</z:hpo> without a history of <z:mp ids='MP_0005048'>thrombosis</z:mp> </plain></SENT>
</text></document>